Cargando…
Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration
Purpose. Determining long-term effects of rheohaemapheresis on the dry form of age-related macular degeneration. Methods. This study evaluates 19 patients, average age of 67.6 years, treated with rheohaemapheresis and 18 patients, average age of 72.8 years, comprising the control group. Minimum foll...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880698/ https://www.ncbi.nlm.nih.gov/pubmed/24455194 http://dx.doi.org/10.1155/2013/135798 |
_version_ | 1782298102550495232 |
---|---|
author | Studnička, Jan Rencová, Eva Bláha, Milan Rozsíval, Pavel Lánská, Miriam Bláha, Vladimír Němčanský, Jan Langrová, Hana |
author_facet | Studnička, Jan Rencová, Eva Bláha, Milan Rozsíval, Pavel Lánská, Miriam Bláha, Vladimír Němčanský, Jan Langrová, Hana |
author_sort | Studnička, Jan |
collection | PubMed |
description | Purpose. Determining long-term effects of rheohaemapheresis on the dry form of age-related macular degeneration. Methods. This study evaluates 19 patients, average age of 67.6 years, treated with rheohaemapheresis and 18 patients, average age of 72.8 years, comprising the control group. Minimum follow up period was 3.5 years. Each treated patient received a series of 8 sessions of rheohaemapheresis of 1.5 plasma volumes within 10 weeks. We measured the drusenoid pigment epithelium detachment (DPED), best-corrected visual acuity (BCVA), electroretinography (ERG), and rheological parameters. Results. In the treatment group, the baseline BCVA was 0.74 (0.36–1.0) 95% CI and BCVA after 3.5 years was 0.79 (0.41–1.0) 95% CI (P = 0.726). In the control group, the baseline BCVA was 0.71 (0.15–1.0) 95% CI and BCVA after 3.5 years decreased to 0.7 (0.32–0.87) 95% CI (P = 0.031). Baseline DPED was 6.78 ± 3.79 mm(2); after 3.5 years, it decreased to 4.13 ± 3.84 mm(2) (P < 0.001). In the control group, the baseline DPED was 4.09 ± 3.48 mm(2); after 3.5 years, it increased to 6.69 ± 4.2 mm(2) (P = 0.001). We noted increasing levels of positive wave peaking at 50 milliseconds (P50) after treatment (P = 0.022) and a stable amplitude of photopic responses of treated patients. Conclusion. Over the long term, rheohaemapheresis reduced the DPED, improved the function of photoreceptors, and prevented the decline of BCVA. |
format | Online Article Text |
id | pubmed-3880698 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-38806982014-01-20 Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration Studnička, Jan Rencová, Eva Bláha, Milan Rozsíval, Pavel Lánská, Miriam Bláha, Vladimír Němčanský, Jan Langrová, Hana J Ophthalmol Clinical Study Purpose. Determining long-term effects of rheohaemapheresis on the dry form of age-related macular degeneration. Methods. This study evaluates 19 patients, average age of 67.6 years, treated with rheohaemapheresis and 18 patients, average age of 72.8 years, comprising the control group. Minimum follow up period was 3.5 years. Each treated patient received a series of 8 sessions of rheohaemapheresis of 1.5 plasma volumes within 10 weeks. We measured the drusenoid pigment epithelium detachment (DPED), best-corrected visual acuity (BCVA), electroretinography (ERG), and rheological parameters. Results. In the treatment group, the baseline BCVA was 0.74 (0.36–1.0) 95% CI and BCVA after 3.5 years was 0.79 (0.41–1.0) 95% CI (P = 0.726). In the control group, the baseline BCVA was 0.71 (0.15–1.0) 95% CI and BCVA after 3.5 years decreased to 0.7 (0.32–0.87) 95% CI (P = 0.031). Baseline DPED was 6.78 ± 3.79 mm(2); after 3.5 years, it decreased to 4.13 ± 3.84 mm(2) (P < 0.001). In the control group, the baseline DPED was 4.09 ± 3.48 mm(2); after 3.5 years, it increased to 6.69 ± 4.2 mm(2) (P = 0.001). We noted increasing levels of positive wave peaking at 50 milliseconds (P50) after treatment (P = 0.022) and a stable amplitude of photopic responses of treated patients. Conclusion. Over the long term, rheohaemapheresis reduced the DPED, improved the function of photoreceptors, and prevented the decline of BCVA. Hindawi Publishing Corporation 2013 2013-12-18 /pmc/articles/PMC3880698/ /pubmed/24455194 http://dx.doi.org/10.1155/2013/135798 Text en Copyright © 2013 Jan Studnička et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Studnička, Jan Rencová, Eva Bláha, Milan Rozsíval, Pavel Lánská, Miriam Bláha, Vladimír Němčanský, Jan Langrová, Hana Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration |
title | Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration |
title_full | Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration |
title_fullStr | Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration |
title_full_unstemmed | Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration |
title_short | Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration |
title_sort | long-term outcomes of rheohaemapheresis in the treatment of dry form of age-related macular degeneration |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880698/ https://www.ncbi.nlm.nih.gov/pubmed/24455194 http://dx.doi.org/10.1155/2013/135798 |
work_keys_str_mv | AT studnickajan longtermoutcomesofrheohaemapheresisinthetreatmentofdryformofagerelatedmaculardegeneration AT rencovaeva longtermoutcomesofrheohaemapheresisinthetreatmentofdryformofagerelatedmaculardegeneration AT blahamilan longtermoutcomesofrheohaemapheresisinthetreatmentofdryformofagerelatedmaculardegeneration AT rozsivalpavel longtermoutcomesofrheohaemapheresisinthetreatmentofdryformofagerelatedmaculardegeneration AT lanskamiriam longtermoutcomesofrheohaemapheresisinthetreatmentofdryformofagerelatedmaculardegeneration AT blahavladimir longtermoutcomesofrheohaemapheresisinthetreatmentofdryformofagerelatedmaculardegeneration AT nemcanskyjan longtermoutcomesofrheohaemapheresisinthetreatmentofdryformofagerelatedmaculardegeneration AT langrovahana longtermoutcomesofrheohaemapheresisinthetreatmentofdryformofagerelatedmaculardegeneration |